Human serum albumin-based nanoparticle-mediated in vitro gene delivery

Monica Langiu, Miriam Dadparvar, Jörg Kreuter, Mika O. Ruonala

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)


The genetic treatment of neurodegenerative diseases still remains a challenging task since many approaches fail to deliver the therapeutic material in relevant concentrations into the brain. As viral vectors comprise the risk of immune and inflammatory responses, human serum albumin (HSA) nanoparticles were found to represent a safer and more convenient alternative. Their ability to cross the blood-brain barrier (BBB) and deliver drugs into the brain in order to enhance genebased therapy has been previously demonstrated. The present study deals with the development of pGL3-PEI-coated HSA nanoparticles and subsequent in vitro testing in cerebellar granular and HeLa cells. The luciferase control vector pGL3 was chosen as reporter plasmid encoding for the firefly luciferase protein, linear polyethylenimine (22 kDa) as endosomolytic agent for enhancing the cells' transfection. Studies on particle characteristics, their cellular uptake into aforementioned cell lines and on subcellular localisation, and transfection efficiency in the cerebellar cells proved the feasibility of nanoparticlebased gene delivery.

Original languageEnglish
Article numbere107603
Number of pages7
JournalPLoS ONE
Issue number9
Publication statusPublished - 17 Sep 2014
Externally publishedYes

Cite this